Paper42444693
2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity.
Huong TTL and 13 others. RSC Adv, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. 2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity. Papers, record 42444693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42444693
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26133355 | Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents. | Med Chem | 2015 | https://conductscience.org/library/papers/26133355 | PubMed |
| 2 | 8744570 | VMD: visual molecular dynamics. | J Mol Graph | 1996 | https://conductscience.org/library/papers/8744570 | PubMed |
| 3 | 17962618 | FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. | Oncologist | 2007 | https://conductscience.org/library/papers/17962618 | PubMed |
| 4 | 28196602 | Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. | Bioorg Chem | 2017 | https://conductscience.org/library/papers/28196602 | PubMed |
| 5 | 37122176 | Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors. | J Enzyme Inhib Med Chem | 2023 | https://conductscience.org/library/papers/37122176 | PubMed |
| 6 | 27573798 | Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification. | Sci Rep | 2016 | https://conductscience.org/library/papers/27573798 | PubMed |
| 7 | 25738536 | Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. | Molecules | 2015 | https://conductscience.org/library/papers/25738536 | PubMed |
| 8 | 11052792 | Prediction of drug absorption using multivariate statistics. | J Med Chem | 2000 | https://conductscience.org/library/papers/11052792 | PubMed |
| 9 | 28177238 | Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity. | J Med Chem | 2017 | https://conductscience.org/library/papers/28177238 | PubMed |
| 10 | 35887396 | Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35887396 | PubMed |
| 11 | 16397526 | Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16397526 | PubMed |
| 12 | 12036371 | Molecular properties that influence the oral bioavailability of drug candidates. | J Med Chem | 2002 | https://conductscience.org/library/papers/12036371 | PubMed |
| 13 | 12429021 | Histone deacetylases (HDACs): characterization of the classical HDAC family. | Biochem J | 2003 | https://conductscience.org/library/papers/12429021 | PubMed |
| 14 | 10490031 | Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. | Nature | 1999 | https://conductscience.org/library/papers/10490031 | PubMed |
| 15 | 33266366 | Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33266366 | PubMed |
| 16 | 27318122 | Inside HDACs with more selective HDAC inhibitors. | Eur J Med Chem | 2016 | https://conductscience.org/library/papers/27318122 | PubMed |
| 17 | 37404064 | Novel hydrazone-isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling. | Arch Pharm (Weinheim) | 2023 | https://conductscience.org/library/papers/37404064 | PubMed |
| 18 | 17694074 | HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. | Oncogene | 2007 | https://conductscience.org/library/papers/17694074 | PubMed |
| 19 | 37805934 | AmberTools. | J Chem Inf Model | 2023 | https://conductscience.org/library/papers/37805934 | PubMed |
| 20 | 24185378 | Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. | Eur J Med Chem | 2013 | https://conductscience.org/library/papers/24185378 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HDAC9 | 9734 | PubTator's text mining | https://conductscience.org/library/genes/9734 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42444693
GET https://conductscience.org/api/papers/v1/42444693/references?page=2